Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

BOTHELL, WA and VANCOUVER, May 14 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the release of two abstracts to be presented during oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts are now available to the public online on the OncoGenex Web site at www.oncogenex.com in addition to the ASCO Web site, www.abstract.asco.org.

Highlights from the OGX-011 Abstract

At the time data was submitted to ASCO and as previously disclosed in December 2008, the preliminary median overall survival in patients with advanced prostate cancer who were treated with OGX-011 plus docetaxel in a randomized Phase 2 trial was 27.5 months compared to 16.9 months for patients treated with docetaxel alone. The hazard ratio (HR), a measure used to determine the difference in survival between treatment groups, was 0.60, representing a 40% reduction in the rate of death for patients treated with OGX-011. New data disclosed today include a prospectively defined multivariate analysis evaluating variables predictive of overall survival. The analysis defined only three variables predictive of overall survival: performance status, presence of visceral metastasis and assignment to the OGX-011 treatment arm. Based on the multivariate analysis, patients treated with OGX-011 had a rate of death 46% lower than patients treated with docetaxel alone (HR=0.54; p=0.04).

The abstract represents survival data as of November 2008. Final survival data as of April 2009 for this trial will be presented during an oral presentation at ASCO.

Highlights from the OGX-427 Abstract

At the time the data was submitted to ASCO, 34 patients with a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , , , , , ... for examining , regulatory promoter and enhancer sequences ... cases, the element under investigation (promoter, enhancer) is cloned , ... subsequently , used to transfect cells. Quantification of ...
... , , , , , ... , , , , ... is an essential step in some of the most innovative , ... the cloning of mammals, and vaccination against cancer. Compared to the , ...
... , , , Note: Genomic DNA is fragile. ... Use suitable large-bore pipet tips or equipment when , pipetting genomic ... Place a 1 cm tail sample into a ... be stored at 20C. To minimize possible cross-contamination, , ...
Cached Biology Technology:Genetic Reporter Systems 2Genetic Reporter Systems 3Genetic Reporter Systems 4Principles and applications of electrical cell fusion 2Principles and applications of electrical cell fusion 3Principles and applications of electrical cell fusion 4Principles and applications of electrical cell fusion 5Mouse Tail Genomic DNA Isolation Protocol(1) 2
(Date:7/10/2014)... everyday household items such as washing machines could hold ... new study has claimed., As part of an EPSRC ... including those from the University of Exeter, have shown ... replicated in the natural world to help restock declining ... in essence a built-in feedback control mechanism to maintain ...
(Date:7/10/2014)... Consuming a whole fresh avocado with either an ... A carotenoid (alpha- and beta-carotene) absorption and conversion of ... according to new research (1) published in ... Vitamin A is involved in reproductive health and growth ... and has antioxidant properties. Provitamin A carotenoids, like alpha- ...
(Date:7/10/2014)... 2014Women in the West African nation Burkina Faso ... option. Sayana Press has the potential to increase ... health system and in communities by combining a ... (depot medroxyprogesterone acetate)with the BD Uniject injection system. ... African countries expected to begin introducing Sayana Press ...
Breaking Biology News(10 mins):Feedback control could be key to robust conservation management 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... Researchers at the University of Granada (UGR) have studied the ... known population of Polygala balansae in Europe, a ... which was previously thought to be exclusive to Morocco. The ... and included on the list of threatened species. In ...
... taking non-oral and oral hormonal contraceptives were at highest ... study of female German medical students published today in ... women taking non-hormonal contraceptives were at lowest risk for ... "Sexual problems can have a negative impact on both ...
... change is happening today, a Kansas State University professor ... forest and grassland ecosystems. Kendra McLauchlan, assistant professor ... Foundation CAREER Award to examine contrasts in vegetation history ... nitrogen cycling and other ecosystem properties. McLauchlan is the ...
Cached Biology News:Polygala balansae, a new bush to Europe, at risk of extinction in Spain 2Hormonal contraceptives associated with higher risk of female sexual dysfunction 2Hormonal contraceptives associated with higher risk of female sexual dysfunction 3K-State professor using NSF award to study the impact of nitrogen deposition on global change 2